Trial Profile
A Single Center, Open-label, Drug Interaction Study of MGL-3196 With Atorvastatin in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Resmetirom (Primary) ; Atorvastatin
- Indications Dyslipidaemias; Hypercholesterolaemia; Hypertriglyceridaemia; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Madrigal Pharmaceuticals
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.
- 28 Apr 2016 New trial record